KDR and neoplasm: Using the NSCLC tumour model, we found that Afatinib suppressed the expression of LYVE-1, VEGFR2, 3, VEGFC, and VEGF in tumour tissues, indicating reduced lymphatic formation and possible VEGFC/VEGFR3 pathway involvement in the process.